Literature DB >> 21799392

Everolimus and long-term outcomes in renal transplantation.

Josep M Campistol1, Johan W de Fijter, Björn Nashan, Hallvard Holdaas, Stefan Vítko, Christophe Legendre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21799392     DOI： 10.1097/TP.0b013e3182230900

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  4 in total

1.  Evaluation of a perforated drug delivery system in mice for prolonged and constant release of a hydrophilic drug.

Authors:  Ashish Rastogi; Phillip D Bowman; Salomon Stavchansky
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

2.  Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients.

Authors:  David J Taber; Lindsey Belk; Holly Meadows; Nicole Pilch; James Fleming; Titte Srinivas; John McGillicuddy; Charles Bratton; Kenneth Chavin; Prabhakar Baliga
Journal:  Ther Drug Monit       Date:  2013-12       Impact factor: 3.681

3.  Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.

Authors:  Klemens Budde; Claudia Sommerer; Thomas Rath; Petra Reinke; Hermann Haller; Oliver Witzke; Barbara Suwelack; Daniel Baeumer; Christian Sieder; Martina Porstner; Wolfgang Arns
Journal:  J Nephrol       Date:  2014-09-06       Impact factor: 4.393

4.  Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.

Authors:  Keith Melancon; Shamkant P Mulgaonkar; Carlos Delcoro; Anne Wiland; Kevin McCague; Fuad S Shihab
Journal:  Transplantation       Date:  2013-12-27       Impact factor: 4.939
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.